Intercure Ltd. INCR
Annual
Quarterly
No annual revenue total was found in INTERCURE LTD.'s SEC filings.
Intercure Ltd. (INCR) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
54.68M
+15.9% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INCR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Herzliya, Israel
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1857030
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Sep 8, 2026 | Sep 8, 2026 |
| 6-K/A | Filing | Aug 27, 2026 | Aug 27, 2026 |
| 6-K | Current report (foreign issuer) | Aug 26, 2026 | Aug 26, 2026 |
| 6-K | Current report (foreign issuer) | Aug 24, 2026 | Aug 24, 2026 |
| 6-K | Current report (foreign issuer) | Aug 11, 2026 | Aug 11, 2026 |
| 6-K | Current report (foreign issuer) | Aug 4, 2026 | Aug 4, 2026 |
All 119 Intercure Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.